General Information of Drug Combination (ID: DCR1VHE)

Drug Combination Name
IT-141 LY03004
Indication
Disease Entry Status REF
Chronic myelogenous leukemia Investigative [1]
Component Drugs IT-141   DMAYD7O LY03004   DME5TUR
N.A. N.A.
High-throughput Screening Result Testing Cell Line: KBM-7
Zero Interaction Potency (ZIP) Score: 1.48
Bliss Independence Score: 1.48
Loewe Additivity Score: 1.91
LHighest Single Agent (HSA) Score: 1.91

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of IT-141
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1 [2]
IT-141 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
DNA topoisomerase I (TOP1) TTGTQHC TOP1_HUMAN Inhibitor [2]
------------------------------------------------------------------------------------
Indication(s) of LY03004
Disease Entry ICD 11 Status REF
Schizophrenia 6A20 Phase 3 [3]

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)